ArticleCureus2024
Quality of Life, Its Determinants, and Psychiatric Comorbidities in Juvenile Myoclonic Epilepsy: A Cross-Sectional Observational Study From North India.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundJuvenile myoclonic epilepsy (JME) is a well-controlled genetic generalized epilepsy (GGE) syndrome with a favourable prognosis but the long-term outcome is still controversial due to the presence of personality traits, executive dysfunction, and psychiatric disorders inherent to this condition. Also, the existing literature on quality of life (QoL) in adolescent patients of JME is sparse. This study was done to assess the QoL, its determinants, and the presence of psychiatric comorbidities in JME. MATERIALS AND
methodsThe study was a hospital-based observational cross-sectional study of 50 participants done over 18 months. Patients of JME aged over 11 years fulfilling the diagnostic and electroencephalographic criteria were included in the study. Adolescent and adult JME participants were interviewed with the Quality of Life in Epilepsy-Adolescents-48 (QOLIE-AD-48) and patient-weighted Quality Of Life in Epilepsy-31 (QOLIE-31-P), respectively, for assessment of QoL, the domains affected, and its impact on overall QoL. They were also screened for psychiatric disorders with Mini International Neuropsychiatric Interview 7.0.2 (M.I.N.I. 7.0.2), a brief diagnostic-structured interview that has modules for each diagnostic category. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) was used for further diagnostic categorization.
resultsFifty patients with JME were enrolled. The mean age was 24.14 ± 7.7 years, of which 32 (64%) were female patients. The overall QOLIE-31-P score in adult JME participants was fair (62.29 ± 25.02). The impacted subdomains in adults were of seizure worry (47.73 ± 24.62) and cognitive functioning (46.41 ± 25.32). The mean QOLIE-48-AD score of adolescent JME study participants was fair (69.71 ± 13.13). The physical functioning (57.36 ± 18.94) and health perception (56.5 ± 16.9) domains were found to be impacted in adolescents. Five (10%) of the patients had anxiety and three (6%) of the participants had depression. A significant association was seen between the occurrence of generalized tonic-clonic seizure (GTCS) frequency (per year) and the presence of psychiatric comorbidity (p-value < 0.05).
conclusionJME may have a negative impact on overall QoL in both adolescents and adults despite adequate seizure control. Fear of seizure recurrence, cognitive issues, negative perception of health, and comorbid psychiatric disorders need to be addressed simultaneously and treated holistically as part of comprehensive epilepsy care to improve long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.